{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:06:29Z","timestamp":1793243189125,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajgponline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Geriatric Psychiatry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jagp.2026.05.016","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:20:41Z","timestamp":1780068041000},"page":"1167-1183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cannabinoids Treatment for Agitation in Alzheimer\u2019s Disease: A Systematic Review and Meta-Analysis With Bayesian and Sequential Trial Analyses"],"prefix":"10.1016","volume":"34","author":[{"given":"Anderson Matheus Pereira","family":"da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Daniel Vicente","family":"de Siqueira Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Figueiroa Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Hugo Pinheiro","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Januario Campos Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduarda Lima","family":"Ornelas Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oc\u00edlio Ribeiro","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Braga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique","family":"Cal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo Santos","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silv\u00e2nia Maria Mendes","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe Silveira","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Anghinah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jagp.2026.05.016_bib0001","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","article-title":"Dementia prevention, intervention, and care: 2024 report of the Lancet Standing Commission","volume":"404","author":"Livingston","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jagp.2026.05.016_bib0002","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jalz.2011.05.2410","article-title":"Neuropsychiatric symptoms in Alzheimer\u2019s disease","volume":"7","author":"Lyketsos","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.jagp.2026.05.016_bib0003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fneur.2012.00073","article-title":"Behavioral and psychological symptoms of dementia","volume":"3","author":"Cerejeira","year":"2012","journal-title":"Front Neurol"},{"key":"10.1016\/j.jagp.2026.05.016_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h369","article-title":"Assessment and management of behavioral and psychological symptoms of dementia","volume":"350","author":"Kales","year":"2015","journal-title":"BMJ"},{"issue":"15","key":"10.1016\/j.jagp.2026.05.016_bib0005","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials","volume":"294","author":"Schneider","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jagp.2026.05.016_bib0006","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fphar.2014.00037","article-title":"Cannabinoids for treatment of Alzheimer disease: moving toward the clinic","volume":"5","author":"Aso","year":"2014","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.jagp.2026.05.016_bib0007","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/jnc.14098","article-title":"Endocannabinoid system in neurodegenerative disorders","volume":"142","author":"Basavarajappa","year":"2017","journal-title":"J Neurochem"},{"issue":"4","key":"10.1016\/j.jagp.2026.05.016_bib0008","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.fbp.0000135704.56422.40","article-title":"CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents","volume":"15","author":"Haller","year":"2004","journal-title":"Behav Pharmacol"},{"issue":"4","key":"10.1016\/j.jagp.2026.05.016_bib0009","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0278-5846(01)00162-2","article-title":"The role of cannabinoids in neurodegenerative diseases","volume":"25","author":"Glass","year":"2001","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.jagp.2026.05.016_bib0010","article-title":"Cannabinoids for the treatment of dementia","author":"Krishnan","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.jagp.2026.05.016_bib0011","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0706743719892717","article-title":"Cannabinoids for the neuropsychiatric symptoms of dementia: a systematic review and meta-analysis","volume":"65","author":"Bahji","year":"2020","journal-title":"Can J Psychiatry"},{"issue":"23","key":"10.1016\/j.jagp.2026.05.016_bib0012","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1212\/WNL.0000000000001675","article-title":"Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial","volume":"84","author":"van den Elsen","year":"2015","journal-title":"Neurology"},{"issue":"10113","key":"10.1016\/j.jagp.2026.05.016_bib0013","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","article-title":"Dementia prevention, intervention, and care","volume":"390","author":"Livingston","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jagp.2026.05.016_bib0014","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.jagp.2026.05.016_bib0015","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jagp.2026.05.016_bib0016","first-page":"181","article-title":"Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: an open-label study","volume":"39","author":"Shelaf","year":"2016","journal-title":"Clin Gerontol"},{"issue":"12","key":"10.1016\/j.jagp.2026.05.016_bib0017","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jagp.2026.05.016_bib0018","first-page":"77","article-title":"Agitation Inventory","volume":"41","author":"Cohen-Mansfield","year":"1986","journal-title":"J Gerontol"},{"issue":"6","key":"10.1016\/j.jagp.2026.05.016_bib0019","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1017\/S1041610210000876","article-title":"The Neuropsychiatric Inventory\u2013Clinician rating scale (NPI-C): reliability and validity","volume":"22","author":"de Medeiros","year":"2010","journal-title":"Int Psychogeriatr"},{"issue":"3","key":"10.1016\/j.jagp.2026.05.016_bib0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.jagp.2026.05.016_bib0021","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1177\/13872877251389608","article-title":"A randomized clinical trial of low-dose cannabis extract in Alzheimer\u2019s disease","volume":"108","author":"Cury","year":"2025","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"10.1016\/j.jagp.2026.05.016_bib0022","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D","article-title":"Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer\u2019s disease","volume":"12","author":"Volicer","year":"1997","journal-title":"Int J Geriatr Psychiatry"},{"issue":"11","key":"10.1016\/j.jagp.2026.05.016_bib0023","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jagp.2019.05.002","article-title":"Randomized placebo-controlled trial of nabilone for agitation in Alzheimer\u2019s disease","volume":"27","author":"Herrmann","year":"2019","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2026.05.016_bib0024","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jagp.2026.05.016_bib0025","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"7109","key":"10.1016\/j.jagp.2026.05.016_bib0026","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.jagp.2026.05.016_bib0027","first-page":"694","article-title":"Actigraphy in agitated patients with dementia: monitoring motor activity patterns","volume":"22","author":"Mahlberg","year":"2007","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6","key":"10.1016\/j.jagp.2026.05.016_bib0028","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jagp.2026.05.016_bib0029","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"15","key":"10.1016\/j.jagp.2026.05.016_bib0030","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1002\/sim.2112","article-title":"How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS","volume":"24","author":"Lambert","year":"2005","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.jagp.2026.05.016_bib0031","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.jagp.2026.05.016_bib0032","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ije\/dyn188","article-title":"Apparently conclusive meta-analyses may be inconclusive\u2014trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses","volume":"38","author":"Brok","year":"2009","journal-title":"Int J Epidemiol"},{"issue":"3","key":"10.1016\/j.jagp.2026.05.016_bib0033","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials","volume":"35","author":"O\u2019Brien","year":"1979","journal-title":"Biometrics"},{"issue":"8","key":"10.1016\/j.jagp.2026.05.016_bib0034","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011890","article-title":"False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review","volume":"6","author":"Imberger","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.jagp.2026.05.016_bib0035","year":"2023","journal-title":"R: A Language and Environment for Statistical Computing"},{"issue":"6","key":"10.1016\/j.jagp.2026.05.016_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v093.i06","article-title":"Bayesian random-effects meta-analysis using the bayesmeta R package","volume":"93","author":"R\u00f6ver","year":"2020","journal-title":"J Stat Softw"},{"key":"10.1016\/j.jagp.2026.05.016_bib0037","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jagp.2026.05.016_bib0038","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Syst Rev"},{"issue":"2","key":"10.1016\/j.jagp.2026.05.016_bib0039","article-title":"Cannabinoid-based medicines for behavioural and psychological symptoms of dementia: a randomized controlled trial","volume":"20","author":"Albertyn","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.jagp.2026.05.016_bib0040","article-title":"Safety and efficacy of cannabinoids for neuropsychiatric symptoms in Alzheimer disease: a randomized clinical trial","volume":"8","author":"Rosenberg","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jagp.2026.05.016_bib0041","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2014.93","article-title":"Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial","volume":"311","author":"Porsteinsson","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jagp.2026.05.016_bib0042","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.0828","article-title":"Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis","volume":"2","author":"Yunusa","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jagp.2026.05.016_bib0043","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","article-title":"Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer\u2019s dementia: two 12-week, randomized, double-blind, placebo-controlled trials","volume":"28","author":"Grossberg","year":"2020","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2026.05.016_bib0044","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jamaneurol.2023.3810","article-title":"Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial","volume":"80","author":"Lee","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jagp.2026.05.016_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102481","article-title":"Pathogenesis, diagnostics, and therapeutics for Alzheimer\u2019s disease: breaking the memory barrier","volume":"101","author":"Kamatham","year":"2024","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.jagp.2026.05.016_bib0046","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jagp.2026.05.016_bib0047","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","article-title":"Alzheimer disease as a clinical-biological construct: an International Working Group recommendation","volume":"81","author":"Dubois","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jagp.2026.05.016_bib0048","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer\u2019s disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.jagp.2026.05.016_bib0049","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jagp.2026.05.016_bib0050","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer\u2019s disease clinical trials","volume":"5","author":"Andrews","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.jagp.2026.05.016_bib0051","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3233\/JAD-191300","article-title":"Health outcome prioritization in Alzheimer\u2019s disease: understanding the ethical landscape","volume":"77","author":"McKeown","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.jagp.2026.05.016_bib0052","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/ana.24001","article-title":"The therapeutics of Alzheimer\u2019s disease: where we stand and where we are heading","volume":"74","author":"Selkoe","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jagp.2026.05.016_bib0053","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jagp.2026.05.016_bib0054","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3233\/JAD-191300","article-title":"Health outcome prioritization in Alzheimer's disease: understanding the ethical landscape","volume":"77","author":"McKeown","year":"2020","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.jagp.2026.05.016_bib0055","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3233\/JAD-140093","article-title":"The potential therapeutic effects of THC on Alzheimer\u2019s disease","volume":"42","author":"Cao","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.jagp.2026.05.016_bib0056","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3233\/JAD-140921","article-title":"Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer\u2019s disease transgenic mice","volume":"42","author":"Cheng","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.jagp.2026.05.016_bib0057","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3233\/JAD-160533","article-title":"Delineating the efficacy of a cannabis-based medicine at advanced stages of dementia in a murine model","volume":"54","author":"Aso","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.jagp.2026.05.016_bib0058","series-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.jagp.2026.05.016_bib0059","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3233\/JAD-160833","article-title":"Discriminative properties of hippocampal hypoperfusion in marijuana users compared to healthy controls: implications for marijuana administration in Alzheimer\u2019s dementia","volume":"56","author":"Amen","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.jagp.2026.05.016_bib0060","series-title":"Early Alzheimer\u2019s disease: developing drugs for treatment","year":"2023"}],"container-title":["The American Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748126004008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748126004008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:23:59Z","timestamp":1784294639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1064748126004008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1064748126004008"],"URL":"https:\/\/doi.org\/10.1016\/j.jagp.2026.05.016","relation":{},"ISSN":["1064-7481"],"issn-type":[{"value":"1064-7481","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoids Treatment for Agitation in Alzheimer\u2019s Disease: A Systematic Review and Meta-Analysis With Bayesian and Sequential Trial Analyses","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Geriatric Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jagp.2026.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}